As MIT, Dharmacon, and Fisher Butt Heads on Scheduling, Court Orders Dates and Mediation | GenomeWeb

It appears that royalty payments and patent rights aren't the only things on which the Massachusetts Institute of Technology and Dharmacon can't agree.

As MIT's breach-of-contract and patent-infringement suit against Dharmacon and its parent company Fisher Scientific moves forward, the parties have been unable to resolve a number of scheduling matters (see table). As such, the US District Court for the District of Massachusetts has handed down a discovery and trial schedule for the litigants.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.